Acurx Pharmaceuticals Inc (ACXP) Stock Price, Quote & News

Company Profile

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant st...

Industry: Biotechnology

Sector: Healthcare

Phone: 917 533 1469

Website: www.acurxpharma.com

Address:

259 Liberty Avenue, Staten Island, United States

EntanglementE Dec. 24 at 12:05 PM

$ACXP Current positioning will be tested as timelines compress uncertainty rather than extend speculation. The window for proof-of-execution is narrowing.

0 · Reply

geothug Dec. 23 at 5:28 PM

$ACXP no gravy from Luci in the last 2 years huh? What a fat slob loser. If you belive in him you better wake up. He's a B rate accountant, not a Dr. Clear out your accounts and run for the hills!

0 · Reply

ernstaugust Dec. 22 at 6:56 PM

$ACXP looks like an higher low for me… waiting for the higher high 😁

1 · Reply

B43nd Dec. 19 at 3:48 PM

$ACXP

0 · Reply

NVDAMillionaire Dec. 19 at 10:42 AM

$ACXP Really good write-up that perfectly summarizes ACXP's present situation. So if you want to bring your ACXP knowledge up to date or just discover ACXP, this is required reading. https://beyondspx.com/quote/ACXP/analysis/acurx-pharmaceuticals-unlocking-value-in-the-antibiotic-resistance-battle-nasdaq-acxp

0 · Reply

Value_Runner Dec. 17 at 4:49 PM

$ACXP hey Luci—gravy is burning you liar!

0 · Reply

Ihavesunshineinmypocket Dec. 15 at 8:26 PM

$ACXP

0 · Reply

flcountryboy Dec. 15 at 4:07 PM

$ACXP The chart says it all...lower lows and lower highs, from inability to fund trials, loss of confidence in execution even if the product is best in class, and SH dilution. Until company can actually announce and verify it has the funds and the trials are eminent, SP will continue down same path toward some type of liquidation. This is a true WS gamble play. Odds are with the house at this point. IMO.

2 · Reply

B43nd Dec. 15 at 2:38 PM

$ACXP

0 · Reply

ernstaugust Dec. 12 at 3:31 PM

$ACXP just for your information 👀😁 $AMC $BYND $GME

0 · Reply

Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals

Nov 12, 2025, 10:11 AM EST - 6 weeks ago

Acurx Pharmaceuticals, Inc. (ACXP) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 7:01 AM EST - 6 weeks ago

Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update

Nov 10, 2025, 8:00 AM EST - 6 weeks ago

Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens

Oct 28, 2025, 8:00 AM EDT - 2 months ago

Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference

Oct 27, 2025, 8:00 AM EDT - 2 months ago

Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update

Oct 9, 2025, 7:30 AM EDT - 2 months ago

Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

Sep 30, 2025, 7:30 AM EDT - 3 months ago

Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection

Sep 3, 2025, 7:01 AM EDT - 4 months ago

Acurx Pharmaceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Closing Bid Price and Stockholder Equity Rules

Aug 12, 2025, 10:13 AM EDT - 4 months ago

Acurx Pharmaceuticals, Inc. (ACXP) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 7:01 AM EDT - 4 months ago

Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update

Jul 31, 2025, 9:25 AM EDT - 5 months ago

Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split

Jul 24, 2025, 7:01 AM EDT - 5 months ago

Acurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update

Jun 17, 2025, 9:47 PM EDT - 6 months ago

Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds

Jun 17, 2025, 7:01 AM EDT - 6 months ago

Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI

Jun 9, 2025, 7:30 AM EDT - 7 months ago

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference

May 13, 2025, 1:59 PM EDT - 8 months ago

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:01 AM EDT - 8 months ago

Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update

Apr 30, 2025, 7:30 AM EDT - 8 months ago

Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update

Apr 28, 2025, 7:30 AM EDT - 8 months ago

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

Apr 17, 2025, 7:30 AM EDT - 8 months ago

Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

Mar 18, 2025, 9:44 AM EDT - 10 months ago

Acurx Pharmaceuticals, Inc. (ACXP) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 7:01 AM EDT - 10 months ago

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Mar 10, 2025, 4:30 PM EDT - 10 months ago

Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering

Mar 7, 2025, 8:00 AM EST - 10 months ago

Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering

Mar 3, 2025, 8:00 AM EST - 10 months ago

Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics

Feb 28, 2025, 8:00 AM EST - 10 months ago

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update

Feb 24, 2025, 8:00 AM EST - 10 months ago

Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

Feb 19, 2025, 8:00 AM EST - 11 months ago

JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors

Jan 7, 2025, 5:00 PM EST - 1 year ago

Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 6, 2025, 5:35 PM EST - 1 year ago

Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 6, 2025, 8:30 AM EST - 1 year ago

Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)

Dec 11, 2024, 11:00 AM EST - 1 year ago

Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025

Dec 9, 2024, 8:00 AM EST - 1 year ago

Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications

Nov 20, 2024, 10:53 AM EST - 1 year ago

Acurx Pharmaceuticals to add up to $1 million in bitcoin for treasury reserve, following MicroStrategy's playbook

Nov 20, 2024, 7:01 AM EST - 1 year ago

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset

Nov 18, 2024, 7:00 AM EST - 1 year ago

Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update

Nov 13, 2024, 11:43 AM EST - 1 year ago

Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:00 AM EST - 1 year ago

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update

Oct 21, 2024, 10:07 AM EDT - 1 year ago

Acurx Ready To Expand Pipeline With Anthrax Treatment

Oct 21, 2024, 7:00 AM EDT - 1 year ago

Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference

Oct 17, 2024, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024

Oct 14, 2024, 1:00 PM EDT - 1 year ago

New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support

Oct 11, 2024, 10:50 AM EDT - 1 year ago

New to the Street Announces Exclusive Bloomberg Lineup for October 11 at 6:30 PM EST

Sep 26, 2024, 7:00 AM EDT - 1 year ago

Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues

Sep 24, 2024, 7:00 AM EDT - 1 year ago

Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium

Aug 26, 2024, 7:00 AM EDT - 1 year ago

ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference

Aug 9, 2024, 10:20 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. (ACXP) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 7:01 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update

EntanglementE Dec. 24 at 12:05 PM

$ACXP Current positioning will be tested as timelines compress uncertainty rather than extend speculation. The window for proof-of-execution is narrowing.

0 · Reply

geothug Dec. 23 at 5:28 PM

$ACXP no gravy from Luci in the last 2 years huh? What a fat slob loser. If you belive in him you better wake up. He's a B rate accountant, not a Dr. Clear out your accounts and run for the hills!

0 · Reply

ernstaugust Dec. 22 at 6:56 PM

$ACXP looks like an higher low for me… waiting for the higher high 😁

1 · Reply

B43nd Dec. 19 at 3:48 PM

$ACXP

0 · Reply

NVDAMillionaire Dec. 19 at 10:42 AM

0 · Reply

Value_Runner Dec. 17 at 4:49 PM

$ACXP hey Luci—gravy is burning you liar!

0 · Reply

Ihavesunshineinmypocket Dec. 15 at 8:26 PM

$ACXP

0 · Reply

flcountryboy Dec. 15 at 4:07 PM

2 · Reply

B43nd Dec. 15 at 2:38 PM

$ACXP

0 · Reply

ernstaugust Dec. 12 at 3:31 PM

$ACXP just for your information 👀😁 $AMC $BYND $GME

0 · Reply

GillyG Dec. 12 at 2:42 PM

$ACXP

0 · Reply

ABnb15 Dec. 12 at 11:31 AM

$ACXP

0 · Reply

GillyG Dec. 11 at 12:00 AM

$ACXP

0 · Reply

GillyG Dec. 9 at 3:38 PM

$ACXP

0 · Reply

Ihavesunshineinmypocket Dec. 9 at 7:56 AM

$ACXP

0 · Reply

CoachHendo Dec. 9 at 2:57 AM

$ACXP

0 · Reply

VolcanicTrades Dec. 8 at 10:41 PM

$ACXP sure seems like it. Chart setting up, volume surge. $5.70-$8 🎯 added some

0 · Reply

GillyG Dec. 8 at 9:27 PM

$ACXP Good news soon📈👀🚀

0 · Reply

ernstaugust Dec. 8 at 8:32 PM

$ACXP It’s time again, right?

0 · Reply

Bonso99 Dec. 8 at 8:31 PM

$ACXP 🚀🚀🚀🚀🚀💫🫡

0 · Reply

GillyG Dec. 8 at 7:56 PM

$ACXP no walls to stop this 📈🚀👀

0 · Reply

JL_TradeZ Dec. 8 at 6:41 PM

$ACXP is bouncing off the bottom and reclaiming the EMAs with solid volume. Tiny float and they’ve been pretty active with research updates and patents lately, so it has room to keep pushing if it holds. Speculative swing but the setup looks clean

0 · Reply

Market Cap	7.30M
Revenue (ttm)	0.00
Net Income (ttm)	-14.10M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	11,900
Avg Vol	80,246
Day's Range	N/A - N/A
Shares Out	2.09M
Stochastic %K	14%
Beta	-1.25
Analysts	Strong Sell
Price Target	$27.00